Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2018

Open Access 01-12-2018 | Research

Differential effects of innate immune variants of surfactant protein-A1 (SFTPA1) and SP-A2 (SFTPA2) in airway function after Klebsiella pneumoniae infection and sex differences

Authors: Nithyananda Thorenoor, Xuesheng Zhang, Todd M. Umstead, E. Scott Halstead, David S. Phelps, Joanna Floros

Published in: Respiratory Research | Issue 1/2018

Login to get access

Abstract

Background

Surfactant Protein-A (SP-A) is a major protein component of surfactant and plays a role in surfactant-related functions and innate immunity. Human SP-A consists of two functional genes, SFTPA1 and SFTPA2, encoding SP-A1 and SP-A2 proteins, respectively and each is identified with numerous genetic variants. These differentially enhance bacterial phagocytosis, with SP-A2 variants being more effective than SP-A1.

Methods

Lung functions of humanized transgenic (hTG) mice that carry different SP-A1 and SP-A2 variants or both variants SP-A1/SP-A2 (6A2/1A0, co-ex), as well as SP-A knockout (KO), were studied. The animals were connected to a flexiVent system to obtain forced oscillation technique (FOT) measurements and the data were analyzed using various models. Lung function was assessed after infection (baseline) and following inhaled methacholine concentrations (0–50 mg/mL).

Results

Here, we investigated the role of SP-A variants on airway function after Klebsiella pneumoniae (Kp) infection (baseline) and following inhaled methacholine. We found that: 1) in the absence of methacholine no significant differences were observed between SP-A1 and SP-A2 variants and/or SP-A knockout (KO) except for sex differences in most of the parameters studied. 2) In response to methacholine, i) sex differences were observed that were reverse of those observed in the absence of methacholine; ii) SP-A2 (1A3) gene variant in males exhibited increased total and central airway resistance (Rrs and Rn) versus all other variants; iii) In females, SP-A2 (1A3) and SP-A1 (6A2) variants had similar increases in total and central airway resistance (Rrs and Rn) versus all other variants; iv) Allele-specific differences were observed, a) with SP-A2 (1A3) exhibiting significantly higher lung functions versus SP-A2 (1A0) in both sexes, except for Crs, and b) SP-A1 (6A2, 6A4) had more diverse changes in lung function in both sexes.

Conclusion

We conclude that, in response to infection and methacholine, SP-A variants differentially affect lung function and exhibit sex-specific differences consistent with previously reported findings of functional differences of SP-A variants. Thus, the observed changes in respiratory function mechanics provide insight into the role and importance of genetic variation of innate immune molecules, such as SP-A, on mechanical consequences of lung function after infection and inhaled substances.
Literature
1.
Phelps DS. Surfactant regulation of host defense function in the lung: a question of balance. Pediatr Pathol Mol Med. 2001;20(4):269–92.CrossRefPubMed
2.
Kishore U, Greenhough TJ, Waters P, Shrive AK, Ghai R, Kamran MF, Bernal AL, Reid KB, Madan T, Chakraborty T. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol. 2006;43(9):1293–315.CrossRefPubMed
3.
Floros J, Wang G, Mikerov AN. Genetic complexity of the human innate host defense molecules, surfactant protein A1 (SP-A1) and SP-A2--impact on function. Crit Rev Eukaryot Gene Expr. 2009;19(2):125–37.CrossRefPubMedCentralPubMed
4.
Wright JR, Youmans DC. Pulmonary surfactant protein a stimulates chemotaxis of alveolar macrophage. Am J Phys. 1993;264(4 Pt 1):L338–44.
5.
Khubchandani KR, Snyder JM. Surfactant protein a (SP-A): the alveolus and beyond. FASEB J. 2001;15(1):59–69.CrossRefPubMed
6.
Mariencheck WI, Savov J, Dong Q, Tino MJ, Wright JR. Surfactant protein a enhances alveolar macrophage phagocytosis of a live, mucoid strain of P. Aeruginosa. Am J Phys. 1999;277(4 Pt 1):L777–86.
7.
Mikerov AN, Umstead TM, Huang W, Liu W, Phelps DS, Floros J. SP-A1 and SP-A2 variants differentially enhance association of Pseudomonas Aeruginosa with rat alveolar macrophages. Am J Physiol Lung Cell Mol Physiol. 2005;288(1):L150–8.CrossRefPubMed
8.
Mikerov AN, Wang G, Umstead TM, Zacharatos M, Thomas NJ, Phelps DS, Floros J. Surfactant protein A2 (SP-A2) variants expressed in CHO cells stimulate phagocytosis of Pseudomonas Aeruginosa more than do SP-A1 variants. Infect Immun. 2007;75(3):1403–12.CrossRefPubMedCentralPubMed
9.
Borron P, McCormack FX, Elhalwagi BM, Chroneos ZC, Lewis JF, Zhu S, Wright JR, Shepherd VL, Possmayer F, Inchley K, et al. Surfactant protein a inhibits T cell proliferation via its collagen-like tail and a 210-kDa receptor. Am J Phys. 1998;275(4 Pt 1):L679–86.
10.
Kremlev SG, Umstead TM, Phelps DS. Effects of surfactant protein a and surfactant lipids on lymphocyte proliferation in vitro. Am J Phys. 1994;267(4 Pt 1):L357–64.
11.
Brinker KG, Garner H, Wright JR. Surfactant protein a modulates the differentiation of murine bone marrow-derived dendritic cells. Am J Physiol Lung Cell Mol Physiol. 2003;284(1):L232–41.CrossRefPubMed
12.
Haque R, Umstead TM, Ponnuru P, Guo X, Hawgood S, Phelps DS, Floros J. Role of surfactant protein-a (SP-A) in lung injury in response to acute ozone exposure of SP-A deficient mice. Toxicol Appl Pharmacol. 2007;220(1):72–82.CrossRefPubMed
13.
LeVine AM, Bruno MD, Huelsman KM, Ross GF, Whitsett JA, Korfhagen TR. Surfactant protein A-deficient mice are susceptible to group B streptococcal infection. J Immunol. 1997;158(9):4336–40.PubMed
14.
LeVine AM, Kurak KE, Bruno MD, Stark JM, Whitsett JA, Korfhagen TR. Surfactant protein-A-deficient mice are susceptible to Pseudomonas Aeruginosa infection. Am J Respir Cell Mol Biol. 1998;19(4):700–8.CrossRefPubMed
15.
Madan T, Reid KB, Clark H, Singh M, Nayak A, Sarma PU, Hawgood S, Kishore U. Susceptibility of mice genetically deficient in SP-A or SP-D gene to invasive pulmonary aspergillosis. Mol Immunol. 2010;47(10):1923–30.CrossRefPubMed
16.
Mikerov AN, Haque R, Gan X, Guo X, Phelps DS, Floros J. Ablation of SP-A has a negative impact on the susceptibility of mice to Klebsiella Pneumoniae infection after ozone exposure: sex differences. Respir Res. 2008;9:77.CrossRefPubMedCentralPubMed
17.
DiAngelo S, Lin Z, Wang G, Phillips S, Ramet M, Luo J, Floros J. Novel, non-radioactive, simple and multiplex PCR-cRFLP methods for genotyping human SP-A and SP-D marker alleles. Dis Markers. 1999;15(4):269–81.CrossRefPubMedCentralPubMed
18.
Karinch AM, Floros J. 5′ splicing and allelic variants of the human pulmonary surfactant protein a genes. Am J Respir Cell Mol Biol. 1995;12(1):77–88.CrossRefPubMed
19.
Floros J, DiAngelo S, Koptides M, Karinch AM, Rogan PK, Nielsen H, Spragg RG, Watterberg K, Deiter G. Human SP-A locus: allele frequencies and linkage disequilibrium between the two surfactant protein a genes. Am J Respir Cell Mol Biol. 1996;15(4):489–98.CrossRefPubMed
20.
Oberley RE, Snyder JM. Recombinant human SP-A1 and SP-A2 proteins have different carbohydrate-binding characteristics. Am J Physiol Lung Cell Mol Physiol. 2003;284(5):L871–81.CrossRefPubMed
21.
Wang G, Bates-Kenney SR, Tao JQ, Phelps DS, Floros J. Differences in biochemical properties and in biological function between human SP-A1 and SP-A2 variants, and the impact of ozone-induced oxidation. Biochemistry. 2004;43(14):4227–39.CrossRefPubMed
22.
Huang W, Wang G, Phelps DS, Al-Mondhiry H, Floros J. Human SP-A genetic variants and bleomycin-induced cytokine production by THP-1 cells: effect of ozone-induced SP-A oxidation. Am J Physiol Lung Cell Mol Physiol. 2004;286(3):L546–53.CrossRefPubMed
23.
Wang G, Phelps DS, Umstead TM, Floros J. Human SP-A protein variants derived from one or both genes stimulate TNF-alpha production in the THP-1 cell line. Am J Physiol Lung Cell Mol Physiol. 2000;278(5):L946–54.CrossRefPubMed
24.
Wang G, Umstead TM, Phelps DS, Al-Mondhiry H, Floros J. The effect of ozone exposure on the ability of human surfactant protein a variants to stimulate cytokine production. Environ Health Perspect. 2002;110(1):79–84.CrossRefPubMedCentralPubMed
25.
Garcia-Verdugo I, Wang G, Floros J, Casals C. Structural analysis and lipid-binding properties of recombinant human surfactant protein a derived from one or both genes. Biochemistry. 2002;41(47):14041–53.CrossRefPubMed
26.
Selman M, Lin HM, Montano M, Jenkins AL, Estrada A, Lin Z, Wang G, DiAngelo SL, Guo X, Umstead TM, et al. Surfactant protein a and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum Genet. 2003;113(6):542–50.CrossRefPubMed
27.
Karinch AM, Deiter G, Ballard PL, Floros J. Regulation of expression of human SP-A1 and SP-A2 genes in fetal lung explant culture. Biochim Biophys Acta. 1998;1398(2):192–202.CrossRefPubMed
28.
Kumar AR, Snyder JM. Differential regulation of SP-A1 and SP-A2 genes by cAMP, glucocorticoids, and insulin. Am J Phys. 1998;274(2 Pt 1):L177–85.
29.
Scavo LM, Ertsey R, Gao BQ. Human surfactant proteins A1 and A2 are differentially regulated during development and by soluble factors. Am J Phys. 1998;275(4 Pt 1):L653–69.
30.
Wang G, Guo X, Floros J. Human SP-A 3'-UTR variants mediate differential gene expression in basal levels and in response to dexamethasone. Am J Physiol Lung Cell Mol Physiol. 2003;284(5):L738–48.CrossRefPubMed
31.
Tagaram HR, Wang G, Umstead TM, Mikerov AN, Thomas NJ, Graff GR, Hess JC, Thomassen MJ, Kavuru MS, Phelps DS, et al. Characterization of a human surfactant protein A1 (SP-A1) gene-specific antibody; SP-A1 content variation among individuals of varying age and pulmonary health. Am J Physiol Lung Cell Mol Physiol. 2007;292(5):L1052–63.CrossRefPubMed
32.
Lopez-Rodriguez E, Pascual A, Arroyo R, Floros J, Perez-Gil J. Human pulmonary surfactant protein SP-A1 provides maximal efficiency of lung interfacial films. Biophys J. 2016;111(3):524–36.CrossRefPubMedCentralPubMed
33.
Phelps DS, Umstead TM, Silveyra P, Hu S, Wang G, Floros J. Differences in the alveolar macrophage proteome in transgenic mice expressing human SP-A1 and SP-A2. J Proteom Genom Res. 2013;1(2):2–26.CrossRefPubMedCentralPubMed
34.
Tsotakos N, Phelps DS, Yengo CM, Chinchilli VM, Floros J. Single-cell analysis reveals differential regulation of the alveolar macrophage actin cytoskeleton by surfactant proteins A1 and A2: implications of sex and aging. Biol Sex Differ. 2016;7:18.CrossRefPubMedCentralPubMed
35.
Mikerov AN, Umstead TM, Gan X, Huang W, Guo X, Wang G, Phelps DS, Floros J. Impact of ozone exposure on the phagocytic activity of human surfactant protein a (SP-A) and SP-A variants. Am J Physiol Lung Cell Mol Physiol. 2008;294(1):L121–30.CrossRefPubMed
36.
Mikerov AN, Hu S, Durrani F, Gan X, Wang G, Umstead TM, Phelps DS, Floros J. Impact of sex and ozone exposure on the course of pneumonia in wild type and SP-A (−/−) mice. Microb Pathog. 2012;52(4):239–49.CrossRefPubMedCentralPubMed
37.
Durrani F, Phelps DS, Weisz J, Silveyra P, Hu S, Mikerov AN, Floros J. Gonadal hormones and oxidative stress interaction differentially affects survival of male and female mice after lung Klebsiella Pneumoniae infection. Exp Lung Res. 2012;38(4):165–72.CrossRefPubMedCentralPubMed
38.
Whitsett JA. Surfactant proteins in innate host defense of the lung. Biol Neonate. 2005;88(3):175–80.CrossRefPubMed
39.
Ledford JG, Goto H, Potts EN, Degan S, Chu HW, Voelker DR, Sunday ME, Cianciolo GJ, Foster WM, Kraft M, et al. SP-A preserves airway homeostasis during Mycoplasma pneumoniae infection in mice. J Immunol. 2009;182(12):7818–27.CrossRefPubMedCentralPubMed
40.
Nathan N, Taytard J, Duquesnoy P, Thouvenin G, Corvol H, Amselem S, Clement A. Surfactant protein a: a key player in lung homeostasis. Int J Biochem Cell Biol. 2016;81(Pt A):151–5.CrossRefPubMed
41.
42.
Vazquez de Lara L, Becerril C, Montano M, Ramos C, Maldonado V, Melendez J, Phelps DS, Pardo A, Selman M. Surfactant components modulate fibroblast apoptosis and type I collagen and collagenase-1 expression. Am J Physiol Lung Cell Mol Physiol. 2000;279(5):L950–7.CrossRefPubMed
43.
Wang G, Myers C, Mikerov A, Floros J. Effect of cysteine 85 on biochemical properties and biological function of human surfactant protein a variants. Biochemistry. 2007;46(28):8425–35.CrossRefPubMedCentralPubMed
44.
Wang G, Taneva S, Keough KM, Floros J. Differential effects of human SP-A1 and SP-A2 variants on phospholipid monolayers containing surfactant protein B. Biochim Biophys Acta. 2007;1768(9):2060–9.CrossRefPubMedCentralPubMed
45.
Mikerov AN, Gan X, Umstead TM, Miller L, Chinchilli VM, Phelps DS, Floros J. Sex differences in the impact of ozone on survival and alveolar macrophage function of mice after Klebsiella Pneumoniae infection. Respir Res. 2008;9:24.CrossRefPubMedCentralPubMed
46.
McGovern TK, Robichaud A, Fereydoonzad L, Schuessler TF, Martin JG. Evaluation of respiratory system mechanics in mice using the forced oscillation technique. J Vis Exp. 2013;75:e50172.
47.
Wang G, Guo X, Diangelo S, Thomas NJ, Floros J. Humanized SFTPA1 and SFTPA2 transgenic mice reveal functional divergence of SP-A1 and SP-A2: formation of tubular myelin in vivo requires both gene products. J Biol Chem. 2010;285(16):11998–2010.CrossRefPubMedCentralPubMed
48.
Hantos Z, Daroczy B, Suki B, Nagy S, Fredberg JJ. Input impedance and peripheral inhomogeneity of dog lungs. J Appl Physiol (1985). 1992;72(1):168–78.CrossRef
49.
Salazar E, Knowles JH. An analysis of pressure-volume characteristics of the lungs. J Appl Physiol. 1964;19:97–104.CrossRefPubMed
50.
Card JW, Zeldin DC. Hormonal influences on lung function and response to environmental agents: lessons from animal models of respiratory disease. Proc Am Thorac Soc. 2009;6(7):588–95.CrossRefPubMedCentralPubMed
51.
Shalaby KH, Gold LG, Schuessler TF, Martin JG, Robichaud A. Combined forced oscillation and forced expiration measurements in mice for the assessment of airway hyperresponsiveness. Respir Res. 2010;11:82.CrossRefPubMedCentralPubMed
52.
Tomioka S, Bates JH, Irvin CG. Airway and tissue mechanics in a murine model of asthma: alveolar capsule vs. forced oscillations. J Appl Physiol. (1985). 2002;93(1):263–70.CrossRef
53.
Evans KL, Bond RA, Corry DB, Shardonofsky FR. Frequency dependence of respiratory system mechanics during induced constriction in a murine model of asthma. J Appl Physiol. (1985). 2003;94(1):245–52.CrossRef
54.
Wagers S, Lundblad LK, Ekman M, Irvin CG, Bates JH. The allergic mouse model of asthma: normal smooth muscle in an abnormal lung? J Appl Physiol. (1985). 2004;96(6):2019–27.CrossRef
55.
Lundblad LK, Irvin CG, Adler A, Bates JH. A reevaluation of the validity of unrestrained plethysmography in mice. J Appl Physiol. (1985). 2002;93(4):1198–207.CrossRef
56.
Bates JH, Lauzon AM, Dechman GS, Maksym GN, Schuessler TF. Temporal dynamics of pulmonary response to intravenous histamine in dogs: effects of dose and lung volume. J Appl Physiol. (1985). 1994;76(2):616–26.CrossRef
57.
Lutchen KR, Greenstein JL, Suki B. How inhomogeneities and airway walls affect frequency dependence and separation of airway and tissue properties. J Appl Physiol. (1985). 1996;80(5):1696–707.CrossRef
58.
Lutchen KR, Hantos Z, Petak F, Adamicza A, Suki B. Airway inhomogeneities contribute to apparent lung tissue mechanics during constriction. J Appl Physiol. (1985). 1996;80(5):1841–9.CrossRef
59.
Mishima M, Balassy Z, Bates JH. Assessment of local lung impedance by the alveolar capsule oscillator in dogs: a model analysis. J Appl Physiol. (1985). 1996;80(4):1165–72.CrossRef
60.
Similowski T, Bates JH. Two-compartment modelling of respiratory system mechanics at low frequencies: gas redistribution or tissue rheology? Eur Respir J. 1991;4(3):353–8.PubMed
61.
Balassy Z, Mishima M, Bates JH. Changes in regional lung impedance after intravenous histamine bolus in dogs: effects of lung volume. J Appl Physiol. (1985). 1995;78(3):875–80.CrossRef
62.
Carey MA, Card JW, Voltz JW, Germolec DR, Korach KS, Zeldin DC. The impact of sex and sex hormones on lung physiology and disease: lessons from animal studies. Am J Physiol Lung Cell Mol Physiol. 2007;293(2):L272–8.CrossRefPubMed
63.
Gannon CJ, Pasquale M, Tracy JK, McCarter RJ, Napolitano LM. Male gender is associated with increased risk for postinjury pneumonia. Shock. 2004;21(5):410–4.CrossRefPubMed
64.
Yancey AL, Watson HL, Cartner SC, Simecka JW. Gender is a major factor in determining the severity of mycoplasma respiratory disease in mice. Infect Immun. 2001;69(5):2865–71.CrossRefPubMedCentralPubMed
65.
Caracta CF. Gender differences in pulmonary disease. Mt Sinai J Med. 2003;70(4):215–24.PubMed
66.
Wang Y, Voelker DR, Lugogo NL, Wang G, Floros J, Ingram JL, Chu HW, Church TD, Kandasamy P, Fertel D, et al. Surfactant protein a is defective in abrogating inflammation in asthma. Am J Physiol Lung Cell Mol Physiol. 2012;301(4):L598–606.CrossRef
Metadata
Title
Differential effects of innate immune variants of surfactant protein-A1 (SFTPA1) and SP-A2 (SFTPA2) in airway function after Klebsiella pneumoniae infection and sex differences
Authors
Nithyananda Thorenoor
Xuesheng Zhang
Todd M. Umstead
E. Scott Halstead
David S. Phelps
Joanna Floros
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2018
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-018-0723-1

Other articles of this Issue 1/2018

Respiratory Research 1/2018 Go to the issue

Research

Long-term preservation of planar cell polarity in reversed tracheal epithelium

Research

Combined diffusing capacity for nitric oxide and carbon monoxide as predictor of bronchiolitis obliterans syndrome following lung transplantation

Research

Regulatory role of heme oxygenase-1 in silica-induced lung injury

Review

Regulation of alveolar macrophage death in acute lung inflammation

Letter to the Editor

Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma

Research

Altered lung biology of healthy never smokers following acute inhalation of E-cigarettes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits